Clinical trial
A Phase 2, Randomized Study of Bortezomib/Dexamethasone With or Without Elotuzumab in Subjects With Relapsed/Refractory Multiple Myeloma
NCT01478048 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized Study of Bortezomib/Dexamethasone With or Without Elotuzumab in Subjects With Relapsed/Refractory Multiple Myeloma
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2011
- Completion date
- April 21, 2017
- Enrollment
- 185 (actual)
- Sites
- 77
Conditions
As the registry lists them; a condition with its own page is linked.